Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) FCF Margin: 2021-2025

Historic FCF Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to 30,144.19%.

  • SAB Biotherapeutics' FCF Margin rose 2195268.00% to 30,144.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 60,134.31%, marking a year-over-year increase of 6282175.00%. This contributed to the annual value of -2,618.65% for FY2024, which is 148794.00% down from last year.
  • SAB Biotherapeutics' FCF Margin amounted to 30,144.19% in Q3 2025, which was up 171.22% from 11,114.37% recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' FCF Margin ranged from a high of 30,144.19% in Q3 2025 and a low of -8,358.96% during Q4 2024.
  • In the last 3 years, SAB Biotherapeutics' FCF Margin had a median value of -414.49% in 2023 and averaged 3,392.21%.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 567,563bps in 2023, then skyrocketed by 2,195,268bps in 2025.
  • Over the past 5 years, SAB Biotherapeutics' FCF Margin (Quarterly) stood at -65.47% in 2021, then tumbled by 1,194bps to -77.41% in 2022, then plummeted by 435,344bps to -4,430.85% in 2023, then slumped by 392,811bps to -8,358.96% in 2024, then soared by 2,195,268bps to 30,144.19% in 2025.
  • Its last three reported values are 30,144.19% in Q3 2025, 11,114.37% for Q2 2025, and 11,208.53% during Q1 2025.